

Available online on 25.12.2017 at <http://jddtonline.info>

## Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Research Article

### PREPARATION AND EVALUATION OF IRBESARTAN-CYCLODEXTRIN INCLUSION COMPLEXES

Rajashree Hirlekar<sup>1</sup>, V. J. Kadam<sup>2</sup><sup>1</sup>Vivekanand Education Society's College of Pharmacy, Chembur, Mumbai-400074<sup>2</sup>Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai-400614

E-mail address: rajashree.hirlekar@ves.ac.in

#### ABSTRACT

In the present work effect of methyl- $\beta$ -cyclodextrin (M $\beta$ CD) on physical properties and dissolution rate of Irbesartan (IRB) was studied. Based on  $A_L$ -type of phase solubility diagram obtained; solid binary systems of the drug with M $\beta$ CD were prepared in 1:1 molar ratio by various methods. Complexes were characterized using Differential Scanning Calorimetry and powder X-Ray Diffractometry. It could be concluded that IRB can form inclusion complex with M $\beta$ CD. The dissolution profiles of inclusion complexes were compared with those of IRB alone and the physical mixture. The dissolution rate of IRB was increased remarkably by M $\beta$ CD inclusion complexation.

**Cite this article as:** Hirlekar R, Kadam VJ, Preparation and evaluation of irbesartan-cyclodextrin inclusion complexes, Journal of Drug Delivery and Therapeutics. 2017; 7(7):18-20

#### INTRODUCTION:

Irbesartan (IRB) is used in the treatment of hypertension. Its poor aqueous solubility leads to limited bioavailability after oral administration<sup>1, 2</sup>. Cyclodextrins (CDs) are macrocyclic oligosaccharides with six to eight D-glucose units called  $\alpha$ -cyclodextrin,  $\beta$ -cyclodextrin and  $\gamma$ -cyclodextrin and have been widely used to improve the solubility and dissolution rate of poorly soluble drugs<sup>3</sup>. Significant improvement in the solubility resulting in increased rate of dissolution and absorbability is obtained by use of methylated  $\beta$ CD.

Co-evaporation, co-grinding and kneading methods were used to prepare inclusion complexes. Instrumental techniques like X-Ray Diffraction (XRD) and Differential Scanning Calorimetry (DSC) were used for characterization of complexes. Dissolution patterns of plain drug, physical mixtures and inclusion complexes were evaluated.

#### MATERIALS AND METHODS:

**Materials:** IRB was kindly supplied by Aarati Drugs Ltd., India. M $\beta$ CD (D.S. = 1.8 and M. W. = 1310) was gifted by Wacker fine chemicals.

**Methods:** Method described by Higuchi and Connors was used to conduct phase solubility studies<sup>1</sup>. An excess amount of IRB was added to M $\beta$ CD aqueous solution (0-10mM) and subjected to shaking. After equilibrium

attainment, concentration of IRB was determined. The apparent stability constant  $K_s$  was calculated from the phase solubility diagram according to the following equation:

$$K_s = \frac{\text{Slope}}{S_0(1 - \text{Slope})}$$

$S_0$  is the solubility of IRB in absence of M $\beta$ CD.


#### Preparation and evaluation of Binary Systems of IRB-M $\beta$ CD:

Various methods such as co-grinding (CG), kneading (KN) and co-evaporation (CE) were used to prepare binary systems of IRB-M $\beta$ CD with 1:1 molar ratio. The physical mixture (PM) was also prepared for the purpose of comparison. Intense trituration of IRB and M $\beta$ CD was carried out to obtain CG product. Trituration of IRB with M $\beta$ CD in glass mortar followed by kneading with 66% alcohol for 45 min resulted in KN product. The pasty mass obtained was dried at 60°C. The dried mass was passed through sieve no.80 and stored overnight in desiccator. For preparation of CE product, equimolar amounts of M $\beta$ CD and IRB were dissolved in minimum volume of 1:1 mixture of 66% ethanol and water. The final solution was stirred with the help of magnetic stirrer at 60°C till pasty mass was obtained. The pasty mass was treated as above to get the dry sample.

Binary systems were characterized by DSC, XRD alongwith dissolution studies. Dissolution rate studies of IRB alone and from various IRB-M $\beta$ CD systems were conducted using USP XXIII dissolution apparatus type-II (6 stations, VDA-6DR, Veego Scientific, India) at  $37 \pm 0.5^\circ\text{C}$  stirring at 50 rpm. Seventy five mg of IRB or its equivalent amount of IRB-M $\beta$ CD binary system was added to 1000 ml of distilled water. At predetermined time intervals, the samples were withdrawn and analyzed spectrophotometrically.

## RESULTS AND DISCUSSION:

The phase solubility profile of IRB-M $\beta$ CD as presented in Figure 1 is classified as A<sub>L</sub> type. The curve showed a linear increase in IRB solubility as a function of M $\beta$ CD concentration with a slope of 0.0904 ( $R^2 = 0.999$ ) in the concentration range (0-10 mM) investigated. The apparent stability constant  $K_{1:1}$  was  $177.8 \text{ M}^{-1}$ . Slope value was lower than one indicating inclusion complex in the molar ratio of 1:1.




**Figure 1:** Phase solubility profile of IRB-M $\beta$ CD in water


Thermograms of IRB and the binary systems are shown in Fig. 2. The thermogram of IRB was typical of a highly crystalline compound, characterized by a sharp endothermic peak at  $181^\circ\text{C}$ , corresponding to its melting. A broad endotherm in the range of  $100\text{-}120^\circ\text{C}$  in case of M $\beta$ CD indicated release of water molecule from its cavity. PM and CG systems showed retention endothermic peaks corresponding to drug whereas it was shifted to lower temperature in the case of CE system. KN system showed a significant shift in location of endothermic peak of IRB to  $158.9^\circ\text{C}$  with substantial broadening which can be attributed to complex formation<sup>5</sup>.

Thus kneading method can be utilized for complexation of IRB using M $\beta$ CD.

XRD patterns of IRB, PM and KN complex are illustrated in Fig. 3. Two broad diffused peak of M $\beta$ CD indicated its amorphous nature. PM and CG systems showed peaks attributable to IRB. The KN and CE systems exhibited more diffused diffraction patterns, indicating loss of crystallinity. Similar disappearance of crystalline drug peak was observed by Bandi et al in case of HP $\beta$ CD complexation of some drugs<sup>5</sup>.




**Figure 2:** DSC thermograms of IRB-M $\beta$ CD systems: Irbesartan (IRB), Methyl- $\beta$ -cyclodextrin (M $\beta$ CD), physical mixture (PM), co-ground (CG), co-evaporated (CE) and kneaded (KN) systems



**Figure 3:** X-Ray Diffractograms of IRB-M $\beta$ CD systems: Irbesartan (IRB), Methyl- $\beta$ -cyclodextrin (M $\beta$ CD), physical mixture (PM), Co-ground (CG), co-evaporated (CE) and kneaded (KN) systems

## Dissolution Studies

Amongst the IRB-M $\beta$ CD systems, KN system showed the highest improvement in the dissolution rate. Thus it can be concluded that KN method was more efficient in improving the solubility when using M $\beta$ CD. The KN method is of the particular interest for industrial scale preparations because of the low cost and the simple process, which involves less energy, time and equipment.



**Figure 4:** The dissolution diagram of IRB-M $\beta$ CD systems

♦ Irbesartan (IRB), ■ physical mixture (PM), ▲ co-ground (CG), × co-evaporated (CE), ∗ kneaded (KN) systems

### CONCLUSION:

From instrumental methods of characterization, it can be concluded that IRB forms inclusion complexes with M $\beta$ CD. The complexes exhibited improvement in solubility and dissolution rate of drug.

### ACKNOWLEDGEMENT:

Authors are thankful to AaratiDrugs Ltd. and Wacker fine chemicals for providing the gift samples.

### REFERENCES:

1. Irbesartan In: (Ed.), Martindale's: The complete drug reference, 34<sup>rd</sup>ed, Pharmaceutical Press, London, 2004, 34<sup>rd</sup>ed, 940.
2. Pouleur HG, A new angiotensin II receptor antagonist, Am J Hyperten, 1997, 10, 318-324.
3. Beker O, Uijtendaal EV, Beijnen JH, Butt A, Underberg WJM, Cyclodextrins in the pharmaceutical field, Drug Dev Ind Pharm, 1991, 17, 1503-1549.
4. Higuchi T, Connors KA (1965) In: C. N. Reilly (Ed.), Advances in Analytical Chemistry and Instrumentation, Interscience, New York, pp117-212.
5. Bandi N, Wei W, Roberts CB, Kotra LP, Kompella UB, Preparation of budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process, EJPS, 2004, 23, 159-168.